Role of genetic polymorphisms in the progression of liver fibrosis in chronic hepatitis C virus infection

Liver International

Volumn 28, Issue 6, 2008, Pages 764-766

  Papatheodoridis, George V ^a   Paraskevis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 2; RANTES; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL ABUSE; AMINO ACID SUBSTITUTION; DIABETES MELLITUS; DISEASE COURSE; EDITORIAL; EXON; FATTY LIVER; GENETIC MARKER; GENETIC POLYMORPHISM; HEPATITIS B; HEPATITIS C; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; POPULATION GENETICS; PROTEIN FUNCTION; RISK FACTOR; SENESCENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 44949114189     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01800.x     Document Type: Editorial

References (20)

1. National Institute of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36 (Suppl. 1): S3-20.
2. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
3. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 2003; 37: 493-503.
4. Selzner N, Chen L, Borozan I, et al. Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients. J Hepatol 2008; 48: 708-13.
5. Dai CY, Chuang WL, Hsieh MY, et al. Polymorphism of interferon-gamma gene at position +874 and clinical characteristics of chronic hepatitis C. Transl Res 2006; 148: 128-33.
6. Dai CY, Chuang WL, Lee LP, et al. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. J Viral Hepat 2006; 13: 770-4.
7. Hellier S, Frodsham AJ, Hennig BJ, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003; 38: 1468-76.
8. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55: 362-9.
9. Abbas Z, Moatter T, Hussainy A, et al. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005; 11: 6656-61.
10. Hennig BJ, Hellier S, Frodsham AJ, et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002; 3: 359-67.
11. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003; 52: 1206-10.
12. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130: 1679-87.
13. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297-306.
14. Kato N, Muroyama R, Dharel N, et al. Association of IRF-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients. Liver Int 2008; 28: 798-806.
15. Colina R, Costa-Mattioli M, Dowling RJ, et al. Translational control of the innate immune response through IRF-7. Nature 2008; 452: 323-8.
16. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res 2006; 16: 141-7.
17. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-7.
18. Barnes BJ, Richards J, Mancl M, et al. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004; 279: 45194-207.
19. Bone-Larson CL, Simpson KJ, Colletti LM, et al. The role of chemokines in the immunopathology of the liver. Immunol Rev 2000; 177: 8-20.
20. Yang Q, Khoury MJ, Friedman J, et al. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005; 34: 1129-37.